Palmitoyl Tetrapeptide-7 (Rigin): What the Research Actually Shows

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on palmitoyl tetrapeptide-7 (Rigin). It is not medical advice, a treatment recommendation, or an endorsement of any product. Palmitoyl tetrapeptide-7 is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

If palmitoyl tripeptide-1 is the half of Matrixyl 3000 that everyone knows about — the collagen-stimulating matrikine that carries the “rebuilds skin from within” marketing — then palmitoyl tetrapeptide-7 is the half that almost nobody can name. It appears on every INCI label alongside palmitoyl tripeptide-1 wherever Matrixyl 3000 is formulated, it has a tradename (Rigin), and it does something genuinely different from its combination partner. Its job is not to stimulate collagen — it is to reduce the chronic low-grade skin inflammation that silently degrades collagen faster than any matrikine can rebuild it.

The concept it addresses — inflammaging — is one of the more important ideas in contemporary skin aging research. Inflammaging refers to the persistent, subclinical inflammatory state that accumulates with age in skin and other tissues, driven by senescent cells, UV-damaged keratinocytes, glycation end-products, and dysregulated immune signaling. This is not the acute, visible inflammation of a wound or a sunburn. It is a quiet, sustained elevation of pro-inflammatory cytokines — particularly interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-alpha (TNF-α) — that continuously upregulates matrix metalloproteinase (MMP) activity, degrading collagen and elastin faster than fibroblasts can replace them.

Palmitoyl tetrapeptide-7 targets this process. Its mechanism — suppression of IL-6 and related cytokines from keratinocytes — is the anti-degradation complement to palmitoyl tripeptide-1’s pro-synthesis signal. The Matrixyl 3000 design rationale is that stimulating collagen production while leaving the inflammatory degradation environment intact is suboptimal; addressing both simultaneously is more effective than either approach alone. This article examines whether the evidence supports that rationale.

Quick Facts

INCI Name

Palmitoyl Tetrapeptide-7

Peptide Sequence

Pal-GQPR (palmitoyl-glycine-glutamine-proline-arginine)

Mechanism Class

Anti-inflammatory signal peptide — IL-6 and TNF-α suppression; anti-inflammaging

Evidence Tier

Pilot / Limited Human Data (primarily as component of Matrixyl 3000)

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Molecular Weight

~723 Da — above the 500 Da passive penetration threshold; palmitoyl chain improves lipid barrier affinity

Found In

Matrixyl 3000® (with Palmitoyl Tripeptide-1); also available as standalone ingredient (tradename: Rigin®)

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Palmitoyl Tetrapeptide-7?

Palmitoyl tetrapeptide-7 (INCI: palmitoyl tetrapeptide-7; tradename Rigin®) is a palmitoylated synthetic tetrapeptide with the sequence Pal-GQPR (palmitoyl-glycine-glutamine-proline-arginine). It is derived from the constant region of immunoglobulin G (IgG) — specifically from a segment of the IgG Fc region involved in immune modulation. The GQPR sequence was identified as having anti-inflammatory properties by Lintner and colleagues at Sederma, who developed the palmitoylated derivative for cosmetic use.

Its mechanism is distinct from every other compound in the Cluster G group. Where argireline and Syn-Ake target the neuromuscular junction, and where palmitoyl tripeptide-1 and original Matrixyl stimulate collagen synthesis, palmitoyl tetrapeptide-7 targets the inflammatory signaling environment that drives collagen degradation. It suppresses the release of interleukin-6 (IL-6) and related pro-inflammatory cytokines from keratinocytes, reducing the MMP upregulation that accelerates extracellular matrix breakdown in aging and UV-damaged skin.

As the anti-inflammatory component of Matrixyl 3000, palmitoyl tetrapeptide-7 provides the rationale for why the combination may be more effective than palmitoyl tripeptide-1 alone: building collagen while simultaneously reducing the environment that degrades it. This dual-action design philosophy — synthesis plus anti-degradation — is what distinguishes Matrixyl 3000 from single-mechanism collagen stimulators like original Matrixyl.

Origins and Development

Rigin was developed by Sederma (now Croda Beauty Actives) as a standalone anti-inflammatory cosmetic active before being incorporated into the Matrixyl 3000 combination. The GQPR sequence was identified from immunoglobulin G research — the IgG Fc region contains sequences with immune-modulatory activity, and Sederma’s researchers identified GQPR as having specific anti-inflammatory properties relevant to skin aging. The palmitoylation was applied using the same delivery strategy as other Sederma peptides: increasing lipophilicity for improved stratum corneum penetration.

Rigin predates Matrixyl 3000 as a commercial product and has its own standalone evidence base, including in vitro cytokine suppression studies and some standalone human data, in addition to the combination evidence from Robinson 2005. This gives palmitoyl tetrapeptide-7 a slightly richer standalone evidence picture than palmitoyl tripeptide-1, which is almost exclusively studied in combination context.

Inflammaging: The Problem Palmitoyl Tetrapeptide-7 Targets

Inflammaging — a portmanteau of inflammation and aging — describes the chronic, low-grade, systemic and tissue-level inflammatory state that accumulates with age and is increasingly recognized as a central driver of multiple aging phenotypes, including skin aging. It is not the acute inflammation of an injury or infection — it does not present with visible redness, heat, or swelling. It is a sustained subclinical elevation of pro-inflammatory mediators, particularly IL-6, IL-1β, and TNF-α, that persists across years and decades.

In skin specifically, inflammaging is driven by multiple converging processes: the accumulation of senescent cells that secrete the senescence-associated secretory phenotype (SASP) — a cocktail of pro-inflammatory cytokines; UV-induced DNA damage that activates NF-κB and AP-1 transcription factors driving cytokine production; advanced glycation end-products (AGEs) that activate RAGE receptors and trigger inflammatory signaling; and declining efficiency of immune regulation that normally constrains cytokine excess.

The consequence for skin architecture is straightforward: elevated IL-6 and related cytokines upregulate MMP-1, MMP-3, and MMP-9, the principal collagenases and gelatinases that degrade dermal collagen and elastin. If MMP activity persistently exceeds fibroblast synthesis capacity, net collagen loss accumulates — a process that no amount of collagen-stimulating peptide can fully offset if the inflammatory environment continues to accelerate degradation.

Plain English

Aging skin has a quiet, ongoing inflammation problem that most people never feel or see. This invisible inflammation activates enzymes that break down collagen continuously. If you’re only adding peptides to stimulate collagen production without addressing that degradation, you’re filling a leaking bucket. Palmitoyl tetrapeptide-7 targets the leak.

Mechanism of Action

Palmitoyl tetrapeptide-7 acts as an immunomodulatory peptide, suppressing pro-inflammatory cytokine production from keratinocytes — the primary epithelial cells of the epidermis and a significant source of inflammatory mediators in aging skin. Its GQPR sequence, derived from the IgG Fc region, interacts with immune signaling pathways to reduce IL-6 secretion, with secondary effects on IL-1β and TNF-α at higher concentrations.

By reducing IL-6 and related cytokines, palmitoyl tetrapeptide-7 indirectly reduces MMP upregulation — the downstream consequence of cytokine-driven inflammatory signaling that accelerates collagen and elastin degradation. The effect is not direct MMP inhibition; it is upstream signal attenuation that reduces the cellular instruction to produce MMPs. This is an important distinction for understanding the mechanism: palmitoyl tetrapeptide-7 does not directly block MMPs, it reduces the inflammatory stimulus that drives their overexpression.

Plain English

The skin’s immune cells release signals (cytokines) that tell enzymes to break down collagen. Palmitoyl tetrapeptide-7 reduces those signals upstream — it doesn’t block the enzymes directly, it tells the cells to stop issuing the order to produce them in excess. The result is less collagen degradation activity, without directly interfering with the degradation enzymes themselves.

This mechanism makes palmitoyl tetrapeptide-7 genuinely complementary to collagen-stimulating peptides rather than merely additive. The synthesis pathway (palmitoyl tripeptide-1) and the anti-degradation pathway (palmitoyl tetrapeptide-7) operate through orthogonal signaling routes — TGF-β/fibroblast activation versus NF-κB/cytokine suppression in keratinocytes — targeting different cell types and different aspects of the net collagen balance equation simultaneously.

Key Research Areas and Studies

In Vitro Cytokine Studies

Sederma’s published technical data for Rigin includes in vitro studies demonstrating dose-dependent suppression of IL-6 secretion from keratinocyte cultures (HaCaT cells) stimulated with pro-inflammatory agents. Reductions in IL-6 of 40–60% were reported at concentrations of 10–100 µM. TNF-α suppression was also observed at higher concentrations. These in vitro findings establish the cytokine-suppression mechanism at the cellular level and are the primary mechanistic evidence for the compound’s anti-inflammatory activity.

Independent academic research on the GQPR sequence specifically is limited — most in vitro data comes from Sederma technical publications. However, the IgG Fc region’s immune-modulatory role is well-characterized in independent immunology research, providing mechanistic plausibility for the GQPR sequence’s anti-inflammatory activity beyond manufacturer data alone. The mechanism is pharmacologically coherent even where the specific compound data is manufacturer-associated.

Standalone Rigin Clinical Data

Sederma published standalone Rigin clinical data from a study of 20 women (ages 40–60) who applied a 3% Rigin formulation to the face twice daily for 60 days. Skin roughness and inflammatory markers were assessed. The study reported reductions in roughness and improvement in skin texture measures, alongside ex vivo cytokine measurements suggesting reduced IL-6 in treated skin samples. This is a small, manufacturer-sponsored study — the same interpretive framework applies as to the other Cluster G ingredient studies — but it provides some standalone clinical signal, not purely combination-context evidence.

Matrixyl 3000 Combination Evidence

The Robinson 2005 Matrixyl 3000 study — 23 women, 3% combination formulation, 60 days — provides the primary human clinical evidence for palmitoyl tetrapeptide-7 functioning in combination with palmitoyl tripeptide-1. The design of the study does not allow attribution of specific effects to either component individually. The combination rationale — synthesis plus anti-degradation — is coherent, and the clinical outcomes are consistent with a formulation addressing both pathways, but whether palmitoyl tetrapeptide-7 specifically contributed to the measured wrinkle outcomes is not separable from the data.

Evidence note: Palmitoyl tetrapeptide-7 has slightly more standalone evidence than palmitoyl tripeptide-1 — the Rigin standalone study provides some clinical signal outside the combination context. Both components remain in the “pilot / limited human data” tier — the standalone study is small (20 women) and manufacturer-sponsored, and the combination evidence does not allow individual attribution.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Reduces skin inflammation” In vitro cytokine suppression is well-demonstrated at tested concentrations. Small standalone clinical study suggests reduced roughness and inflammatory markers. Mechanism is pharmacologically coherent via IgG Fc-derived sequence. Supported in vitro; modest clinical signal from small standalone study
“The anti-aging half of Matrixyl 3000” Accurate framing of its role in the combination — it provides the anti-inflammaging complement to palmitoyl tripeptide-1’s collagen synthesis signal. Both components contribute to the anti-aging rationale of the combination. Mechanistically accurate
“Clinically proven to reduce wrinkles as a standalone” The standalone Rigin study measured skin roughness and texture, not wrinkle depth specifically. The wrinkle reduction evidence comes from the Matrixyl 3000 combination study, in which the individual contribution of palmitoyl tetrapeptide-7 is not separable. Overstated — wrinkle evidence is combination context; standalone evidence is texture/roughness
“Works the same as niacinamide for inflammation” Niacinamide has extensive independent clinical evidence across multiple mechanisms including inflammation, pigmentation, and barrier function. Palmitoyl tetrapeptide-7 has manufacturer-sponsored data on cytokine suppression. The evidence bases are not comparable in size or independence. No basis for equivalence — different compounds, different evidence depth
“SC injection delivers it more effectively” No published injection data. Palmitoyl chemistry is designed for topical delivery. The target — keratinocytes — is in the epidermis, the most superficially accessible skin layer. SC injection bypasses both the delivery mechanism and the target cell location. No evidence; rationale is particularly weak — the target cells are epidermal, not deep

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Palmitoyl tetrapeptide-7 has a slightly stronger standalone evidence picture than palmitoyl tripeptide-1, primarily because Rigin was developed and studied as a standalone ingredient before being incorporated into Matrixyl 3000. The standalone Rigin study (20 women, 60 days) provides some clinical data outside the combination context. This remains a small, manufacturer-sponsored study — it does not approach the design quality of the original Matrixyl 2003 study or the independence of a large academic RCT.

The inflammaging mechanism that palmitoyl tetrapeptide-7 targets is increasingly well-recognized in mainstream dermatology research. IL-6 suppression and anti-inflammaging strategies appear more frequently in the independent dermatology literature than in earlier cosmetic peptide research periods, which provides some contextual validation for the ingredient’s mechanistic rationale even absent large independent clinical trials of the compound itself. This is circumstantial support — the disease mechanism is validated; the compound’s effect on it at cosmetic concentrations in living skin is manufacturer-demonstrated but not independently replicated at scale.

A notable point specific to palmitoyl tetrapeptide-7 among the Cluster G compounds: its target cells — keratinocytes — are in the epidermis. The epidermis is the most superficially accessible skin layer. This means topical penetration to the target cell population is more readily achievable for palmitoyl tetrapeptide-7 than for compounds targeting dermal fibroblasts (which require deeper penetration) or the neuromuscular junction (which requires the deepest penetration of all). The penetration challenge for this compound’s primary mechanism is meaningfully lower than for the NMJ-targeting peptides.

Safety, Risks, and Limitations

Topical Safety

Palmitoyl tetrapeptide-7 has an excellent topical safety profile, consistent with the broader Matrixyl 3000 record. Decades of commercial use in the Matrixyl 3000 combination and as standalone Rigin have not produced significant adverse event signals. Contact sensitization is rare. The ingredient is well-tolerated across skin types. Its immunomodulatory mechanism — suppressing IL-6 production — operates at concentrations well below those that would produce systemic immune effects, and topical absorption limits systemic exposure to negligible levels.

Microneedling Safety Considerations

For palmitoyl tetrapeptide-7 specifically, the microneedling rationale is worth examining more critically than for other Cluster G compounds. The primary target — keratinocytes — is in the epidermis, the layer that microneedling penetrates and partially disrupts. This raises an interesting formulation question: does microneedling during active channel formation and tissue disruption create the right environment for an anti-inflammatory signal? The microinjury of microneedling itself produces an inflammatory response that is part of its mechanism of action for stimulating collagen — applying an anti-inflammatory peptide immediately into that wound environment may partially counteract the intended inflammatory stimulus. This is a theoretical consideration, not an established clinical finding, but it is worth noting for practitioners designing microneedling protocols.

Post-microneedling application — applied after the channels have closed (12–24 hours) rather than immediately — sidesteps this concern and may be a more appropriate protocol for anti-inflammatory peptides specifically. The standard cosmetic sterility caveats apply regardless of timing.

Subcutaneous Injection Safety

No published SC injection data exists. For palmitoyl tetrapeptide-7 specifically, the SC injection rationale is arguably the weakest of any compound in this cluster. The target cells — keratinocytes — are epidermal, located at the skin surface, not in the deep dermal or subdermal compartments accessible by SC injection. SC-injected palmitoyl tetrapeptide-7 would need to distribute systemically, cross back into the epidermis against its concentration gradient, and reach keratinocytes at concentrations sufficient for cytokine suppression. This is not how the compound is designed to work. The palmitoyl delivery chemistry, SC targeting challenge, non-sterile source material, and absence of any published safety data combine to make SC injection of this compound the least justifiable injection approach in the Cluster G group.

Safety Note

Among the Cluster G compounds, palmitoyl tetrapeptide-7 has the least coherent rationale for SC injection — its target cells (keratinocytes) are in the epidermis, the most superficially accessible skin layer. SC injection would need to deliver the compound systemically and then have it accumulate specifically in epidermal keratinocytes against its concentration gradient. There is no mechanism by which this would produce the targeted IL-6 suppression in keratinocytes that topical application achieves directly.

Legal and Regulatory Status

Palmitoyl tetrapeptide-7 is a cosmetic ingredient regulated under standard cosmetic frameworks in the US and EU. No FDA pre-market approval is required for cosmetic use. In the EU, it falls under Regulation EC 1223/2009. The ingredient is available as standalone Rigin from Sederma/Croda, and as a generic palmitoyl tetrapeptide-7 from multiple cosmetic ingredient suppliers. It is permitted in cosmetic formulations without specific concentration restrictions in either jurisdiction.

Marketing claims must remain within cosmetic claim boundaries. “Reduces the appearance of skin aging associated with inflammation” is a cosmetic claim. Claims about modulating immune function or treating inflammatory skin conditions cross into drug claim territory and are not appropriate for this ingredient in cosmetic formulations. WADA status: not prohibited.

Research Protocols and Formulation Considerations

Concentration: Sederma recommends 1–3% Rigin in finished formulations. The Matrixyl 3000 combination study used 3% total blend. Standalone Rigin study data at 3% provides some clinical anchoring. Commercial products range from 0.5–2%, with the same concentration-disclosure gap that applies across all Cluster G compounds.

Stability: Palmitoyl tetrapeptide-7 is stable across pH 4.5–7.5, compatible with most cosmetic actives. Acidic formulations (pH below 4) risk peptide degradation — the same vitamin C compatibility consideration applies as to other cosmetic peptides.

Combination with other anti-inflammatories: Palmitoyl tetrapeptide-7’s IL-6 suppression mechanism operates via the NF-κB/cytokine pathway. Niacinamide also has anti-inflammatory activity (different mechanism: PGE2 and cytokine suppression via distinct pathways). Combining both may provide complementary anti-inflammaging coverage through different molecular targets. As with all cosmetic ingredient combinations, whether the combination produces meaningfully greater clinical benefit than either alone has not been studied in published clinical trials.

Standalone vs. Matrixyl 3000: Formulators who prefer standalone palmitoyl tetrapeptide-7 over the full Matrixyl 3000 combination can pair it with other collagen-stimulating actives — original Matrixyl (palmitoyl pentapeptide-4), retinol, or vitamin C — while retaining control over each component’s concentration. This approach requires more formulation complexity but allows more precise dosing of each mechanism.

Dosing and Delivery: What the Research Shows

Topical Application

The standalone Rigin study and the Matrixyl 3000 combination study both used 3% formulations applied twice daily for 60 days. These are the evidence anchors. Sederma recommends 1–3% in finished formulations. The penetration challenge for palmitoyl tetrapeptide-7 to reach its primary target (epidermal keratinocytes) is lower than for compounds targeting deeper structures — the epidermis is the first tissue encountered by a topically applied ingredient. This may mean that effective keratinocyte concentrations are achievable at lower overall applied concentrations than for dermis-targeting or NMJ-targeting peptides.

Microneedling / Stamping

Microneedling application of palmitoyl tetrapeptide-7 raises the timing consideration noted in the safety section: microneedling itself produces a controlled inflammatory response that activates fibroblast collagen synthesis. Applying an anti-inflammatory peptide immediately into the wound environment may partially attenuate this intended response. Post-procedure application after channel closure (12–24 hours) may be more appropriate than simultaneous application during needling, particularly if the goal is to reduce post-procedure inflammation and support the repair phase rather than to deliver the peptide specifically via microneedling channels. No published protocol data exists for this specific consideration.

Subcutaneous Injection

No published data. For palmitoyl tetrapeptide-7, SC injection is particularly difficult to justify on pharmacological grounds. The target cells — keratinocytes — are epidermal. SC injection deposits compound in subcutaneous tissue, from which it enters systemic circulation. For the compound to reach epidermal keratinocytes from systemic circulation, it would need to traverse the dermis and accumulate in the epidermis against normal physiological gradients. This is not the intended delivery strategy and there is no evidence it would produce targeted keratinocyte IL-6 suppression. Cosmetic-grade material is not manufactured to injectable standards.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks / Considerations
Topical serum/cream Common — primarily as component of Matrixyl 3000; standalone Rigin less common in community use Standalone Rigin study (20 women, 60 days, 3%); combination evidence (Robinson 2005); in vitro cytokine data Low — excellent safety record; epidermal target accessibility is better than deeper-targeting compounds
Microneedling / stamping Less common as standalone; occasionally included in DIY Matrixyl 3000 microneedling solutions No specific trials; timing consideration re: microneedling inflammatory response warrants attention Moderate — sterility of source material; potential conflict between anti-inflammatory mechanism and microneedling inflammatory stimulus; post-procedure timing may be preferable
SC injection Rare — limited community reports; not well-recognized as an injectable target No published data Higher — weakest pharmacological rationale of any Cluster G compound for SC injection; epidermal target is most accessible topically, not via systemic delivery; non-sterile source material

Community use of palmitoyl tetrapeptide-7 as a standalone is limited compared to other Cluster G compounds — most self-experimenters encounter it only as a component of Matrixyl 3000 and do not distinguish between its contribution and that of palmitoyl tripeptide-1. The ingredient is underappreciated in community discussion relative to its mechanistic contribution to the Matrixyl 3000 combination. Among formulators and more technically sophisticated community members, Rigin is increasingly recognized as the “anti-inflammaging” component that addresses the degradation side of the collagen balance equation — the half of skin aging that collagen-stimulating peptides alone cannot fully address.

Frequently Asked Questions

Q: What is palmitoyl tetrapeptide-7 and what does it do?

A: Palmitoyl tetrapeptide-7 (tradename Rigin®, INCI: palmitoyl tetrapeptide-7) is an anti-inflammatory peptide derived from the constant region of immunoglobulin G (IgG). Its GQPR sequence suppresses IL-6 and related pro-inflammatory cytokines from keratinocytes — the primary skin surface cells. By reducing these cytokines, it indirectly lowers the activity of matrix metalloproteinases (MMPs) that degrade collagen and elastin in aging skin. It is one of the two active components of Matrixyl 3000, providing the anti-inflammaging complement to palmitoyl tripeptide-1's collagen-stimulating activity.

Q: Is palmitoyl tetrapeptide-7 the same as Matrixyl 3000?

A: No. Matrixyl 3000 is a combination of two peptides: palmitoyl tripeptide-1 (collagen-stimulating matrikine) and palmitoyl tetrapeptide-7 (anti-inflammatory, IL-6 suppression). Palmitoyl tetrapeptide-7 is one half of that combination. A product INCI list containing "palmitoyl tetrapeptide-7" without "palmitoyl tripeptide-1" contains the anti-inflammatory component of Matrixyl 3000 but not the collagen-stimulating component. Both are present when the product contains both INCI names.

Q: What is inflammaging and why does it matter for skin?

A: Inflammaging describes the chronic, low-grade, subclinical inflammatory state that accumulates in skin with age. Unlike acute inflammation (the visible redness of a wound or sunburn), inflammaging is invisible — a persistent elevation of pro-inflammatory cytokines, particularly IL-6 and TNF-α, that continuously upregulates the enzymes (MMPs) that degrade collagen and elastin. Over decades, this quietly degrades the structural scaffold of skin faster than fibroblasts can rebuild it. Palmitoyl tetrapeptide-7 targets this process by reducing cytokine production at the source — keratinocytes — reducing the inflammatory signal that drives excessive MMP activity.

Q: How is palmitoyl tetrapeptide-7 different from palmitoyl tripeptide-1?

A: They do completely different jobs. Palmitoyl tripeptide-1 stimulates fibroblasts to produce more collagen — it addresses the synthesis side of the collagen balance equation. Palmitoyl tetrapeptide-7 suppresses the inflammatory cytokines that activate enzymes to degrade collagen — it addresses the degradation side. The Matrixyl 3000 combination puts both in the same formulation on the rationale that addressing only one side of the equation is less effective than addressing both simultaneously. The two peptides are complementary, not redundant.

Q: Does palmitoyl tetrapeptide-7 have evidence as a standalone ingredient?

A: Yes, more than its partner palmitoyl tripeptide-1. Sederma published standalone Rigin clinical data from a study of 20 women (60 days, 3% formulation) showing improvements in skin roughness and texture. In vitro cytokine suppression studies demonstrate IL-6 reduction at tested concentrations. Neither the standalone study nor the combination evidence (Robinson 2005) reaches the design quality of an independent large RCT, but palmitoyl tetrapeptide-7 has slightly more standalone evidence than its Matrixyl 3000 partner.

Q: Should palmitoyl tetrapeptide-7 be applied before or after microneedling?

A: This is worth thinking about carefully. Microneedling works partly by creating a controlled inflammatory response that stimulates collagen synthesis — applying an anti-inflammatory peptide immediately into that wound environment may partially counteract the intended inflammatory signal. Post-procedure application (12–24 hours after channels have closed, during the repair phase rather than the acute inflammatory phase) may be more appropriate for anti-inflammatory peptides specifically. This is a theoretical consideration based on mechanism — no published protocol study exists. Standard sterility caveats apply regardless of timing.

Q: Is palmitoyl tetrapeptide-7 worth using if I'm already using niacinamide?

A: They operate through related but distinct anti-inflammatory pathways. Niacinamide reduces inflammation through prostaglandin E2 (PGE2) and cytokine suppression via different molecular targets than palmitoyl tetrapeptide-7's IL-6/NF-κB pathway. The mechanisms are complementary rather than redundant. Whether combining both produces meaningfully greater clinical benefit than either alone has not been studied in a published clinical trial — this is a reasonable formulation choice based on mechanistic logic, not a confirmed additive effect.

Q: Is SC injection of palmitoyl tetrapeptide-7 effective?

A: This has the least pharmacological justification of any compound in the Cluster G group for SC injection. Palmitoyl tetrapeptide-7's primary target cells — keratinocytes — are in the epidermis, the most superficially accessible layer of skin. SC injection deposits the compound in subcutaneous tissue from which it enters systemic circulation; it would then need to accumulate in epidermal keratinocytes against normal physiological gradients. The palmitoyl chemistry is designed for topical lipid barrier penetration, not systemic delivery. No published data exists. Topical application is the evidence-supported route and directly reaches the target cells.

PART-B FILE:

Palmitoyl tetrapeptide-7 is the only dedicated anti-inflammatory peptide in the Cluster G group — every other compound in this cluster targets collagen synthesis or neuromuscular contraction. Its closest functional analogs outside this cluster are compounds like niacinamide (different mechanism, far larger independent evidence base) and centella asiatica-derived actives. Within the Matrixyl 3000 context, its partner palmitoyl tripeptide-1 provides the collagen-synthesis complement. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison across mechanisms, evidence tiers, and delivery route data.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

Palmitoyl tetrapeptide-7 is the most overlooked compound in the Cluster G group and arguably one of the most mechanistically important. It is the anti-inflammaging half of Matrixyl 3000, addressing the collagen degradation side of skin aging rather than the synthesis side. The inflammaging mechanism it targets is well-characterized in independent research. Its own evidence — in vitro cytokine suppression, a standalone 20-woman clinical study, and the Matrixyl 3000 combination evidence — is modest but internally consistent. Among the Cluster G compounds, it has the most favorable penetration profile for its primary target (epidermal keratinocytes) and the least coherent rationale for SC injection.

  • Palmitoyl tetrapeptide-7 (Pal-GQPR, tradename Rigin®) is derived from the IgG Fc region. It suppresses IL-6 and related cytokines from keratinocytes, reducing the MMP upregulation that drives collagen degradation in aging skin.
  • It is the anti-inflammatory component of Matrixyl 3000 — not a collagen stimulator. Its partner palmitoyl tripeptide-1 handles collagen stimulation; palmitoyl tetrapeptide-7 handles reducing collagen degradation. The two mechanisms are complementary, not redundant.
  • It is the only dedicated anti-inflammatory peptide in the Cluster G group. Every other compound targets synthesis or NMJ contraction.
  • Standalone Rigin clinical data: 20 women, 60 days, 3% formulation — small, manufacturer-sponsored, measures texture/roughness rather than wrinkle depth. Some standalone signal, but limited by design and size.
  • Primary target cells (keratinocytes) are epidermal — the most superficially accessible skin layer. This means topical delivery to target is more readily achievable for this compound than for dermis-targeting or NMJ-targeting peptides in this cluster.
  • Microneedling timing consideration: anti-inflammatory application immediately during microneedling may counteract the intended inflammatory stimulus. Post-procedure application (12–24 hours after) may be preferable for anti-inflammatory peptides specifically.
  • SC injection has the least coherent rationale of any Cluster G compound — epidermal target, systemic delivery, palmitoyl topical chemistry, no published data.
  • WADA: not prohibited. Regulatory: cosmetic ingredient, not a drug.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):185–95. PMID 18492182 — primary Matrixyl 3000 combination clinical study
  2. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9. PMID 24833586 — foundational inflammaging framework
  3. Sederma technical dossier: Rigin® / Matrixyl 3000. Clinical and in vitro data on file, Croda Beauty Actives. Available at: sederma.fr
  4. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  5. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
  6. Campisi J, et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183–192. PMID 31292558 — inflammaging and senescence context

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

Palmitoyl tetrapeptide-7 is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. Rigin® is a registered trademark of Sederma/Croda; generic palmitoyl tetrapeptide-7 from other manufacturers is chemically equivalent at the same concentration.

All citations link to primary sources where available. Manufacturer-sponsored studies are identified as such. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.

Scroll to Top